Childhood cancer survivors can be at risk for developing the following splenic and immunologic late effects:
- Chronic Hepatitis B
- Chronic Hepatitis C
- HIV Infection
- Functional Asplenia
- Immunologic Complications
- Secretory IgA Deficiency
- Hypogammaglobulinemia
- Decreased B Cells
- T cell Dysfunction
- Chronic Infections
|
If your patient does not have a Survivor Health Plan (SHP), please refer him/her to the appropriate survivor clinic.
Important factors in determining risk for splenic and immunologic late effects:
-
Total dose of radiation
-
Exposure to blood/serum products prior to 1972: Hepatitis B
-
Exposure to blood/serum products prior to 1993: Hepatitis C
-
Exposure to blood/serum products between 1977-1985: HIV
-
Ongoing immunosuppression
-
Hypogammaglobulinemia
-
HPV infection
-
Practices that predispose to sexual or blood transmission of Hepatitis or HIV
|
Time of Treatment
|
Chronic Hepatitis B
|
Chronic Hepatitis C
|
HIV Infection
|
Diagnoses Prior to 1972
|
X
|
|
|
Diagnosed Prior to 1993
|
|
X
|
|
Diagnosed between 1977 and 1985
|
|
|
X
|
Chemotherapy
Table 1
|
Functional Asplenia
|
Immunologic Complications
|
Alkylating Agents
Carmustine
BCNU
Busulfan
Lomustine
CCNU
Chlorambucil Cyclophosphamide
Cytoxan
Ifosphamide
Mechlorethamine
Melphalan
Procarbazine
Thiotepa
Dacarbazine
DTIC
Temozolomide
|
|
|
Heavy Metals
Carboplatin
Cisplatin
|
|
|
Antimetabolites
Cytarabine
Ara-C
Mercaptopurine
6MP
Thioguanine
6TG
Methotrexate
|
|
|
Anthracycline antibiotics
Daunorubicin
Doxorubicin
Adriamycin
Epirubicin
Idarubicin
Mitoxantrone
|
|
|
Chemotherapy
Table 2
|
Functional Asplenia
|
Immunologic Complications
|
Anti-tumor antibiotics
Bleomycin
Dactinomycin
|
|
|
Corticosteroids
Dexamethasone
Decadron
Prednisone
|
|
|
Enzymes
Asparaginase
|
|
|
Plant alkaloids
Vincristine
Vinblastine
|
|
|
Epipodophyllotoxins
Etoposide
VP16
Teniposide
VM26
|
|
|
Radiation
|
Functional Asplenia
|
Immunologic Complications
|
All Radiation
|
|
|
TBI
|
|
|
Head/Brain
|
|
|
Neck
|
|
|
Thorax
|
|
|
Abdomen
|
>
40 Gy
Include TBI in
total dose
calculation
|
|
Pelvis
|
|
|
Extremity
|
|
|
Hematopoetic Stem Cell Transplant
|
Functional Asplenia
|
Immunologic Complications
|
Hematopoeitic Stem Cell
Transplant with ANY
history of
chronic Graft vs. Host Disease
(GVHD)
|
|
X
|
Hematopoeitic Stem Cell
Transplant currently active
chronic GVHD
|
X
|
|
Surgery
|
Functional Asplenia
|
Immunologic Complications
|
Splenectomy
|
X
|
|
|